Lupus drug belimumab may shield organs from damage, new study hopes to prove
NCT ID NCT07056621
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is tracking 684 people with lupus to see if the drug belimumab can prevent serious organ damage (called BILAG A flares) better than standard care alone. Researchers are using real-world data from clinics in Greece, comparing patients on belimumab to those on usual treatments. The goal is to find out if belimumab changes the long-term course of lupus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belimumab
What this could lead to
If successful, this could show that belimumab helps prevent serious organ damage in lupus patients, supporting its use as a long-term disease control treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also early-stage real-world evidence, not a definitive proof of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital 'Attikon'
RECRUITINGAthens, Attica, 12462, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact